OPTUMRX, INC. Insurance Complaints in 2023
Year-in-review analysis of 39 insurance complaints filed against OPTUMRX, INC. during 2023, based on public NAIC and state DOI data.
Key Statistics
- Complaints in 2023: 39
- Total Complaints (All Time): 103
- 2023 Share: 37.9%
- Coverage Types: 1
- States Affected: 1
- AI Risk Score: 43/100
2023 Complaint Analysis for OPTUMRX, INC.
In 2023, OPTUMRX, INC. received 39 insurance complaints from consumers across 1 state and 1 coverage type. This represents 37.9% of OPTUMRX, INC.'s all-time complaint volume.
The leading category was health with 39 complaints.
Geographically, Texas led with 39 complaints.
2023 Complaints by Category
| Coverage Type | Complaints | % |
|---|---|---|
| health | 39 | 100.0% |
2023 Complaints by State
| State | Complaints |
|---|---|
| Texas | 39 |
OPTUMRX, INC. Complaints from 2023
- health Complaint #TX-380616-24c1665d — Texas (2023-12-18)
- health Complaint #TX-380615-ae6598bf — Texas (2023-12-18)
- health Complaint #TX-380604-24c1665d — Texas (2023-12-18)
- health Complaint #TX-380601-24c1665d — Texas (2023-12-18)
- health Complaint #TX-380596-be880eed — Texas (2023-12-18)
- health Complaint #TX-380594-ae6598bf — Texas (2023-12-18)
- health Complaint #TX-380593-ae6598bf — Texas (2023-12-18)
- health Complaint #TX-380591-ae6598bf — Texas (2023-12-18)
- health Complaint #TX-380581-840865bc — Texas (2023-12-18)
- health Complaint #TX-380580-840865bc — Texas (2023-12-18)
Frequently Asked Questions
How many complaints did OPTUMRX, INC. receive in 2023?
OPTUMRX, INC. received 39 insurance complaints in 2023, according to NAIC and state DOI data.
What types of complaints were filed against OPTUMRX, INC. in 2023?
The most common types: health (39).
Which states had the most complaints against OPTUMRX, INC. in 2023?
Top states: Texas (39).
Is OPTUMRX, INC.'s complaint volume increasing or decreasing?
OPTUMRX, INC.'s complaint history: 2026 (2), 2025 (3), 2024 (5), 2023 (39), 2022 (3), 2021 (2), 2018 (6), 2017 (9), 2016 (11), 2015 (11), 2014 (7), 2013 (5).